Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue.
CD4-positive T lymphocytes
CD8-positive T lymphocytes
Genetic transcription
Immunohistochemistry
Oral cavity
Regulatory T lymphocytes
Squamous cell carcinoma
Tongue
Tumor infiltrating lymphocytes
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
17
07
2020
accepted:
22
09
2020
pubmed:
4
10
2020
medline:
15
12
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
The tumor immune microenvironment of oral tongue squamous cell carcinoma may be accountable for differences in clinical behavior, particularly between different age groups. We performed RNA expression profiling and evaluated tumor infiltrating lymphocytes (TILs) and their T-cell subsets in order to assess the functional status of oral tongue squamous cell carcinoma tumor microenvironment and detect potentially clinically useful associations. Archival surgical pathology material from sixteen oral tongue squamous cell carcinoma patients was microscopically evaluated for TIL densities. RNA was extracted from macrodissected whole tumor sections and normal controls and RNA expression profiling was performed by the NanoString PanCancer IO 360 Gene Expression Panel. Immunostains for CD4, CD8 and FOXP3 were evaluated manually and by digital image analysis. Oral tongue squamous cell carcinomas had increased TIL densities, numerically dominated by CD4 + T cells, followed by CD8 + and FOXP3 + T cells. RNA expression profiling of tumors versus normal controls showed tumor signature upregulation in inhibitory immune signaling (CTLA4, TIGIT and PD-L2), followed by inhibitory tumor mechanisms (IDO1, TGF-β, B7-H3 and PD-L1). Patients older than 44 years showed a tumor microenvironment with increased Tregs and CTLA4 expression. Immunohistochemically assessed CD8% correlated well with molecular signatures related to CD8 + cytotoxic T-cell functions. FOXP3% correlated significantly with CTLA4 upregulation. CTLA4 molecular signature could be predicted by FOXP3% assessed by immunohistochemistry (R
Identifiants
pubmed: 33010009
doi: 10.1007/s12105-020-01229-w
pii: 10.1007/s12105-020-01229-w
pmc: PMC8134601
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-522Subventions
Organisme : Mayo Clinic
ID : Institutional Research Funds
Références
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630659
Front Immunol. 2015 Aug 07;6:394
pubmed: 26300882
Nat Commun. 2015 Mar 26;6:6692
pubmed: 25809635
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Nat Rev Immunol. 2002 May;2(5):309-22
pubmed: 12033737
Cancer Med. 2020 Jul;9(13):4791-4807
pubmed: 32383556
N Engl J Med. 2000 May 4;342(18):1350-8
pubmed: 10793168
Cancer Immunol Res. 2018 Sep;6(9):1069-1081
pubmed: 30018045
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8
pubmed: 18635688
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Cell. 2008 Aug 8;134(3):392-404
pubmed: 18692464
Oral Dis. 2021 Mar;27(2):173-182
pubmed: 32583572
Front Oncol. 2018 Aug 29;8:310
pubmed: 30211111
Adv Immunol. 2007;96:41-101
pubmed: 17981204
Front Oncol. 2018 Oct 15;8:442
pubmed: 30460193
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):433-438
pubmed: 32298244
Oral Dis. 2020 Oct;26(7):1414-1423
pubmed: 32406589
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Br J Cancer. 2019 Apr;120(7):714-727
pubmed: 30808992
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):415-26
pubmed: 26169947
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Pathology. 2016 Oct;48(6):574-80
pubmed: 27590194
Int J Cancer. 2016 Aug 1;139(3):574-83
pubmed: 27038013
Laryngoscope. 2021 Feb;131(2):304-311
pubmed: 32297993
Ann Oncol. 2017 Aug 01;28(8):1934-1941
pubmed: 28460011
Pathol Oncol Res. 2020 Apr;26(2):735-742
pubmed: 30767115
Pathol Oncol Res. 2018 Jul;24(3):497-505
pubmed: 28669079
Am J Clin Pathol. 2015 Aug;144(2):278-88
pubmed: 26185313
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Exp Med. 2012 Feb 13;209(2):211-5
pubmed: 22330683
Annu Rev Immunol. 2018 Apr 26;36:579-601
pubmed: 29677476
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
Histopathology. 2020 Jul;77(1):79-91
pubmed: 32281132
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Br J Cancer. 2003 Aug 18;89(4):605-11
pubmed: 12915864
Nat Immunol. 2019 Sep;20(9):1220-1230
pubmed: 31285626
Oral Oncol. 2018 Dec;87:43-48
pubmed: 30527242
Head Neck. 2019 Jan;41(1):198-207
pubmed: 30536665
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Int J Oral Sci. 2020 May 28;12(1):16
pubmed: 32461587
Cancer Immunol Res. 2019 Oct;7(10):1700-1713
pubmed: 31387897
J Oral Pathol Med. 2019 Jan;48(1):24-30
pubmed: 30357923
Eur J Cancer. 2019 Nov;121:210-223
pubmed: 31593831
Laryngoscope Investig Otolaryngol. 2020 Feb 21;5(2):235-242
pubmed: 32337355
J Clin Oncol. 2011 Apr 10;29(11):1488-94
pubmed: 21383286
Clin Cancer Res. 2016 Feb 1;22(3):704-13
pubmed: 26408403
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Oncol Lett. 2019 Aug;18(2):1372-1380
pubmed: 31423200
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Int J Oral Maxillofac Surg. 2018 May;47(5):568-577
pubmed: 28969885
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Cancer Res. 2017 Nov 15;77(22):6365-6374
pubmed: 28947422
Clin Cancer Res. 2014 Jul 15;20(14):3842-8
pubmed: 24874835
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Nat Immunol. 2019 Jun;20(6):724-735
pubmed: 30936494
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9331-6
pubmed: 18599457
Head Neck. 2015 Nov;37(11):1642-9
pubmed: 24954188
Oncol Rev. 2014 Jun 30;8(1):244
pubmed: 25992232
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
Mol Cancer. 2020 Jul 17;19(1):116
pubmed: 32680511
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Am J Surg Pathol. 2019 Oct;43(10):1392-1396
pubmed: 31290758
Anticancer Res. 2016 Oct;36(10):5499-5506
pubmed: 27798921
Int J Med Sci. 2018 Nov 22;15(14):1723-1730
pubmed: 30588196
Lab Invest. 2007 May;87(5):403-8
pubmed: 17401434